Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees

Abstract Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Ming Low, Yue Gu, Melissa Shu Feng Ng, Zubair Amin, Le Ye Lee, Yvonne Peng Mei Ng, Bhuvaneshwari D/O Shunmuganathan, Yuxi Niu, Rashi Gupta, Paul Anantharajah Tambyah, Paul A. MacAry, Liang Wei Wang, Youjia Zhong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/749b499ea3534b56a5678b0ba67e1df9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:749b499ea3534b56a5678b0ba67e1df9
record_format	dspace
spelling	oai:doaj.org-article:749b499ea3534b56a5678b0ba67e1df92021-12-02T18:51:50ZCodominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees10.1038/s41541-021-00370-z2059-0105https://doaj.org/article/749b499ea3534b56a5678b0ba67e1df92021-08-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00370-zhttps://doaj.org/toc/2059-0105Abstract Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination is still unclear. In this study, we show that lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific IgA and IgG antibodies into milk, with the most significant increase at 3–7 days post-dose 2. Virus-specific IgG titers were stable out to 4–6 weeks after dose 2. In contrast, SARS-CoV-2-specific IgA levels showed substantial decay. Vaccine mRNA was detected in few milk samples (maximum of 2 ng/ml), indicative of minimal transfer. Additionally, infants who consumed post-vaccination human milk had no reported adverse effects up to 28 days post-ingestion. Our results define the safety and efficacy profiles of the vaccine in this demographic and provide initial evidence for protective immunity conferred by milk-borne SARS-CoV-2-specific antibodies. Taken together, our study supports recommendations for uninterrupted breastfeeding subsequent to mRNA vaccination against COVID-19.Jia Ming LowYue GuMelissa Shu Feng NgZubair AminLe Ye LeeYvonne Peng Mei NgBhuvaneshwari D/O ShunmuganathanYuxi NiuRashi GuptaPaul Anantharajah TambyahPaul A. MacAryLiang Wei WangYoujia ZhongNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jia Ming Low Yue Gu Melissa Shu Feng Ng Zubair Amin Le Ye Lee Yvonne Peng Mei Ng Bhuvaneshwari D/O Shunmuganathan Yuxi Niu Rashi Gupta Paul Anantharajah Tambyah Paul A. MacAry Liang Wei Wang Youjia Zhong Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
description	Abstract Lactating women can produce protective antibodies in their milk after vaccination, which has informed antenatal vaccination programs for diseases such as influenza and pertussis. However, whether SARS-CoV-2-specific antibodies are produced in human milk as a result of COVID-19 vaccination is still unclear. In this study, we show that lactating mothers who received the BNT162b2 vaccine secreted SARS-CoV-2-specific IgA and IgG antibodies into milk, with the most significant increase at 3–7 days post-dose 2. Virus-specific IgG titers were stable out to 4–6 weeks after dose 2. In contrast, SARS-CoV-2-specific IgA levels showed substantial decay. Vaccine mRNA was detected in few milk samples (maximum of 2 ng/ml), indicative of minimal transfer. Additionally, infants who consumed post-vaccination human milk had no reported adverse effects up to 28 days post-ingestion. Our results define the safety and efficacy profiles of the vaccine in this demographic and provide initial evidence for protective immunity conferred by milk-borne SARS-CoV-2-specific antibodies. Taken together, our study supports recommendations for uninterrupted breastfeeding subsequent to mRNA vaccination against COVID-19.
format	article
author	Jia Ming Low Yue Gu Melissa Shu Feng Ng Zubair Amin Le Ye Lee Yvonne Peng Mei Ng Bhuvaneshwari D/O Shunmuganathan Yuxi Niu Rashi Gupta Paul Anantharajah Tambyah Paul A. MacAry Liang Wei Wang Youjia Zhong
author_facet	Jia Ming Low Yue Gu Melissa Shu Feng Ng Zubair Amin Le Ye Lee Yvonne Peng Mei Ng Bhuvaneshwari D/O Shunmuganathan Yuxi Niu Rashi Gupta Paul Anantharajah Tambyah Paul A. MacAry Liang Wei Wang Youjia Zhong
author_sort	Jia Ming Low
title	Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
title_short	Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
title_full	Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
title_fullStr	Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
title_full_unstemmed	Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
title_sort	codominant igg and iga expression with minimal vaccine mrna in milk of bnt162b2 vaccinees
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/749b499ea3534b56a5678b0ba67e1df9
work_keys_str_mv	AT jiaminglow codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT yuegu codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT melissashufengng codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT zubairamin codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT leyelee codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT yvonnepengmeing codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT bhuvaneshwaridoshunmuganathan codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT yuxiniu codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT rashigupta codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT paulanantharajahtambyah codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT paulamacary codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT liangweiwang codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees AT youjiazhong codominantiggandigaexpressionwithminimalvaccinemrnainmilkofbnt162b2vaccinees
_version_	1718377391125954560

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees

Ejemplares similares